FDA grants breakthrough therapy designation to Ifinatamab Deruxtecan for lung cancer patients
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension
        Subscribe To Our Newsletter & Stay Updated